Nanthealth LLC (NYSE:NH) shares hit a new 52-week low during trading on Friday . The company traded as low as $12.36 and last traded at $12.56, with a volume of 54,235 shares trading hands. The stock had previously closed at $12.64.

A number of research firms recently issued reports on NH. Jefferies Group began coverage on Nanthealth in a report on Monday, June 27th. They set a “buy” rating on the stock. Canaccord Genuity began coverage on Nanthealth in a report on Monday, June 27th. They set a “buy” rating and a $17.00 target price on the stock. Cowen and Company began coverage on Nanthealth in a report on Monday, June 27th. They set an “outperform” rating and a $19.00 target price on the stock. FBR & Co began coverage on Nanthealth in a report on Monday, June 27th. They set an “outperform” rating and a $18.00 target price on the stock. Finally, First Analysis began coverage on Nanthealth in a report on Monday, June 27th. They set an “overweight” rating and a $18.00 target price on the stock. Five analysts have rated the stock with a buy rating, Nanthealth has an average rating of “Buy” and a consensus target price of $18.00.

The firm’s 50-day moving average price is $13.72 and its 200-day moving average price is $13.72. The company’s market capitalization is $6.94 billion.

In other Nanthealth news, CEO Patrick Soon-Shiong acquired 357,143 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The shares were bought at an average price of $14.00 per share, with a total value of $5,000,002.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Healthcare Solution Allscripts acquired 714,286 shares of Nanthealth stock in a transaction on Tuesday, June 7th. The stock was acquired at an average cost of $14.00 per share, for a total transaction of $10,000,004.00. Following the purchase, the insider now owns 15,000,000 shares of the company’s stock, valued at approximately $210,000,000. The disclosure for this purchase can be found here.

Nant Health, LLC is an evidence-based, personalized healthcare company. The Company’s systems-based approach to personalized healthcare applies diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with real-time biometric signal and phenotypic data to track patient outcomes and deliver medicine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.